Info@LongevityBiotech.com
www.longevitybiotech.com
215-689-1042

Longevity Biotech Receives Funding from Department of Defense to Evaluate LBT-3627 as Novel Treatment for ALS

Longevity Biotech receives support to evaluate a cell-free immunomodulatory approach towards ALS disease modification

Philadelphia, PA, April 1, 2020 – Longevity Biotech, Inc. (LBT), a privately-held biotech company, received significant funding from the Congressionally Directed Medical Research Programs (CDMRP), a part of the Department of Defense, to evaluate LBT-3627 in an animal model of amyotrophic lateral sclerosis (ALS) and ALS patient blood samples. Using a set of novel precision neuroscience markers (Immune Fingerprints), this program aims to study ALS patient immune system profiles and evaluate the ability of LBT-3627 to restore a 'healthy immune balance' in an animal model of ALS.

ALS is rapidly progressing neurological disease with a severely underserved patient population with very limited treatment options. Approximately 90% of ALS patients have a sporadic (non-genetic) form of the disease. Longevity proposes that the disease state occurs when the immune system transitions to an autoimmune state, leading to chronic degeneration. Accordingly, Longevity aims to rebalance the two halves of the immune system (pro- and anti-inflammatory) towards a 'normal', non-degenerative state.

This project endeavors to evaluate LBT-3627 in both the SOD1 animal model of ALS as well as an in vitro treatment of human ALS patient blood samples. Biomarker endpoints will also be explored.

"This project is meaningful in the context of our precision neuroscience efforts here at Longevity Biotech." said CEO Dr. Scott Shandler, Ph.D. "By expanding to include ALS patient data, we aim to further our ability to select the most appropriate patient population for treatment using our novel immune rebalancing approach."

"Numerous literature reports have suggested various roles of the immune system in the progression of ALS. Should LBT-3627 be able to correct the autoimmune imbalance in ALS patients with immune dysfunction, this would represent a significant opportunity to deliver a meaningful treatment option to these patients." said Dr. Sarah Olmstead, Ph.D., project leader at Longevity Biotech.

As part of Longevity Biotech's precision neuroscience strategy, this project will attempt to profile various human immune cells for both function and phenotype. The results of these efforts will be used to help identify specific populations of patients with immune dysfunction, across the continuum of neurodegenerative disorders.

The long-term goal is to evaluate LBT-3627 in a highly targeted clinical trial of ALS patients in the future.

Info@LongevityBiotech.com
www.longevitybiotech.com
215-689-1042

ABOUT AMYOTROPHIC LATERAL SCLEROSIS

Amyotrophic lateral sclerosis (ALS) is a rare progressive neurodegenerative disorder resulting in rapid loss of muscle control. ALS, commonly known as Lou Gehrig's Disease is a Motor Neuron Disease with early symptoms including muscle cramps and muscle twitching, weakness in hands, legs, feet or ankles, difficulty speaking or swallowing. The cause of ALS is unknown with only approximately 10% of patients having a genetic link to the disease. The overwhelming majority of patients have sporadic ALS – meaning there is no genetic basis for the disease. Most people live about 3-5 years after experiencing their ALS symptoms, with one in ten people surviving for at least 10 years. No therapy has been shown to either prevent, cure or even slow the course of ALS.

ABOUT LONGEVITY BIOTECH, INC

Longevity Biotech, Inc. (LBT) is a privately held, biopharmaceutical company focused on changing the landscape of neurodegeneration by pursuing precision neuroscience. LBT develops innovative products with unique attributes that are expected to provide either first-in-class or best-in-class product profiles in their respective indication. Additionally, Longevity Biotech's Precision Biomarker Program aims to identify patient populations that will uniquely benefit from LBT's therapeutic candidates. For more information, visit https://www.longevitybiotech.com/.

ABOUT THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

The office of the Congressionally Directed Medical Research Programs (CDMRP) manages Congressional Special Interest Medical Research Programs (CSI) encompassing breast, prostate, and ovarian cancers, neurofibromatosis, military health, and other specified areas. Since fiscal year 1992, the CDMRP has managed over $19.7 billion in Congressional appropriations for peer-reviewed research aimed at advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. Through fiscal year 2022, approximately 20,385 awards have been made to advance health care solutions via extramural grants, contracts, and cooperative agreements. More information can be found here: https://cdmrp.health.mil/alsrp/default

CONTACT:

Longevity Biotech, Inc.

Tel: +1 215-689-1042

Public Relations

Email: pr@LongevityBiotech.com

Info@LongevityBiotech.com
www.longevitybiotech.com
215-689-1042

Clinical Trials

Email: clinical@LongevityBiotech.com

Business Development

Email: bd@LongevityBiotech.com

SOURCE Longevity Biotech, Inc.

###